WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. HIV関連リポジストロフィーの治療 treatment of hiv associated lipodystrophy
2. 避妊のための酢酸メドロキシプロゲステロンデポ剤 depot medroxyprogesterone acetate for contraception
3. 資源の限られた状況における子宮頸癌のスクリーニング screening for cervical cancer in resource limited settings
4. βサラセミアの治療 treatment of beta thalassemia
5. 去勢抵抗性前立腺癌に対する二次内分泌療法 secondary endocrine therapies for castration resistant prostate cancer

Does Cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study.

Hamid AM1, Madkour WA, Moawad A, Elzaher MA, Roberts MP.
Archives of gynecology and obstetrics.Arch Gynecol Obstet.2014 Oct;290(4):677-82. doi: 10.1007/s00404-014-3242-4. Epub 2014 Apr 20.
AIM: The aim of this study was to compare the efficiency of dopamine agonist, Cabergoline, in decreasing the size of endometrioma, with that of luteinizing hormone releasing hormone (LHRH) agonist, triptorelin acetate.STUDY: This was a prospective, randomized study.SETTING: The setting was in two pr
PMID 24748338

Differential involvement of signaling pathways in the regulation of growth hormone release by somatostatin and growth hormone-releasing hormone in orange-spotted grouper (Epinephelus coioides).

Wang B1, Qin C1, Zhang C1, Jia J1, Sun C1, Li W2.
Molecular and cellular endocrinology.Mol Cell Endocrinol.2014 Feb 15;382(2):851-9. doi: 10.1016/j.mce.2013.10.025. Epub 2013 Oct 29.
Somatostatin is the most effective inhibitor of GH release, and GHRH was recently identified as one of the primary GH-releasing factors in teleosts. In this study, we analyzed the possible intracellular transduction pathways that are involved in the mechanisms induced by SRIF and GHRH to regulate GH
PMID 24183819

Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.

Anda T1, Honda M, Ishihara T, Kamei T.
Neurologia medico-chirurgica.Neurol Med Chir (Tokyo).2014;54(4):327-30. Epub 2013 Nov 8.
The authors describe a male patient who developed a large intracranial meningioma during the hormone therapy for pre-existing prostate cancer. A 70-year-old man received a brain check-up, and no intracranial abnormality was detected. Five months later, prostate cancer was diagnosed, and he underwent
PMID 24201100